Lixte Biotechnology Holdings Inc
LIXT
Get informed when a big investor buys or sells
+ FollowMarket Cap$77.39M
Close$
$0.09
98.6% downside
Current Fair Value
98.6% downsideOvervalued by 98.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $77.39 Million |
|---|---|
| Enterprise Value | $75.20 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.26 |
| Beta | 1.05 |
| Outstanding Shares | 10,889,003 |
Return
| Return on Equity | -76523.61% |
|---|---|
| Return on Assets | -55956.36% |
| Return on Invested Capital | -52994.92% |
Valuation & Multiples
| P/E Ratio | -9.36 |
|---|---|
| PEG | -5.39 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.01 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.13 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Lixte Biotechnology Holdings Inc
4 employeesLixte Biotechnology Holdings, Inc. is a biotech company that identifies enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. Lixte's product pipeline is primarily focused on inh...